EP Patent

EP2433644A1 — Breast cancer therapeutics

Assigned to IMBA Institut fur Molekulare Biotechonologie GmbH · Expires 2012-03-28 · 14y expired

What this patent protects

The present invention relates to a method of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of a RANKL inhibitor to said patient.

USPTO Abstract

The present invention relates to a method of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of a RANKL inhibitor to said patient.

Drugs covered by this patent

Patent Metadata

Patent number
EP2433644A1
Jurisdiction
EP
Classification
—
Expires
2012-03-28
Drug substance claim
No
Drug product claim
No
Assignee
IMBA Institut fur Molekulare Biotechonologie GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.